Masimo Option Alert: Mar 21 $165 Calls at the Ask: 300 vs 13 OI; Earnings 2/25 After Close 

Masimo Option Alert: Mar 21 $165 Calls at the Ask: 300 @ $18.0 vs 13 OI; Earnings 2/25 After Close Ref=$176.175

Masimo (NASDAQ:MASI) 주식

Masimo

Masimo Corp is a technology company. The company's segment includes healthcare and non-healthcare. The healthcare business segment is a key revenue driver, develops, manufactures, and markets a variety of noninvasive patient monitoring technologies, hospital automation and connectivity solutions, remote monitoring devices and consumer health products. Its non-healthcare segment includes consumer audio business develops, manufactures, markets sells and licenses premium and luxury audio sound products and related integration technologies.

Equities

Large Cap

News

Movers

Trading Ideas

ERIE

FICO

LINE

MASI

NTNX

XPEV

지난주에 성과가 가장 좋았던 12개 대형주는 다음과 같다. 헤이코 샤오펑 리오토 리니지 이리 인뎀니티로이즈 뱅킹 유넘 페어 아이작 마시모 스미스 앤 네퓨 앤하이저부시 인베브 뉴타닉스

샤오펑·리오토·뉴타닉스 등 지난주 급등한 대형주 12종목 (2월 24일~28일)

Deal Dispatch

Asset Sales

Restaurants

DBRG

INRE

파산 블록 TGI 프라이데이스가 텍사스에서 챕터 11 파산 신청을 하며 재정적 구제를 위한 &#34;마지막 선택&#34;을 했다. 애피타이저, 윙 요리 및 칵테일로 유명한 이 레스토랑 체인은 재정 구조를 재편성하고 &#34;미래를 위한 전략적 대안 탐색&#34;을 시도하는 동안 39개의 회사 소유 매장을 계속 운영할 계획이다.

딜 디스패치: TGI 프라이데이스가 파산, BHP가 발언을 철회 등 더 많은 M&amp;A 뉴스

Why It Matters

AAPL

SSNLF

지난주는 애플(NASDAQ:AAPL)에게 롤러코스터와 같은 한 주였다. 미국의 조사로 인해 아이폰 칩 생산이 위협받기도 했고, 아이폰의 새로운 판매 기록이 세워지기도 했다. 이러한 발전들 가운데, 애플은 또한 특허 분쟁에 휘말렸고 주요 스트리밍 서비스들이 애플의 앱 스토어에서 이탈하는 것을 목격했다. 지난주에 발생한 주요 사건들을 요약하면 다음과 같다.

주간 주요 애플 뉴스: 기록적인 아이폰 판매부터 법률 및 규제 문제까지

Masimo Corp

Masivo Silver Corp

Needham analyst Mike Matson reiterates Masimo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NASDAQ">MASI</a>) from Hold to Hold.

Reiteration

Analyst Ratings

Needham Reiterates Hold on Masimoto Hold

Masimo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NASDAQ">MASI</a>) has outperformed the market over the past 10 years by 6.02% on an annualized basis producing an average annual return of 15.25%. Currently, Masimo has a market capitalization of $7.80 billion. 
Buying $100 In MASI: If an investor had bought $100 of MASI stock 10 years ago, it would be worth $417.46 today based on a price of $144.40 for MASI at the time of writing.
<h3>Masimo's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743807609_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today

Masimo's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NYSE">MASI</a>) short percent of float has risen 12.22% since its last report. The company recently reported that it has 3.37 million shares sold short, which is 11.48% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.49 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Masimo Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742916616_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Masimo has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Masimo's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Masimo's peer group average for short interest as a percentage of float is 3.79%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Is The Market Feeling About Masimo?

Masimo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NASDAQ">MASI</a>) has outperformed the market over the past 15 years by 2.1% on an annualized basis producing an average annual return of 13.19%. Currently, Masimo has a market capitalization of $9.00 billion. 
Buying $1000 In MASI: If an investor had bought $1000 of MASI stock 15 years ago, it would be worth $6,318.61 today based on a price of $168.16 for MASI at the time of writing.
<h3>Masimo's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742395511_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Masimo 15 Years Ago Would Be Worth This Much Today

Masimo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NASDAQ">MASI</a>) has outperformed the market over the past 10 years by 8.17% on an annualized basis producing an average annual return of 18.91%. Currently, Masimo has a market capitalization of $9.40 billion. 
Buying $100 In MASI: If an investor had bought $100 of MASI stock 10 years ago, it would be worth $570.38 today based on a price of $175.61 for MASI at the time of writing.
<h3>Masimo's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741359691_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 10 Years Ago, You Would Have This Much Today

These twelve large-cap stocks were the best performers in the last week. Are they in your portfolio?
<ol>
<li>Heico (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HEI#NYSE">HEI</a>) stock escalated 17.31% after the company reported better-than-expected <a href="https://www.benzinga.com//node/43990234" target="_blank" rel="noreferrer noopener">first-quarter financial results</a>.</li>
<li>Xpeng (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>) shares jumped 16.79%. Erajaya Active Lifestyle announced the official <a href="https://www.benzinga.com/topic/electric-vehicle" target="_blank" rel="noreferrer noopener">launch of XPENG in Indonesia</a>.</li>
<li>Li Auto (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LI#NASDAQ">LI</a>) stock jumped 11.91% after the company announced its first Electric SUV. JP Morgan analyst Nick Lai upgraded from Neutral to Overweight and raised the price <a href="https://www.benzinga.com/quote/li/analyst-ratings" target="_blank" rel="noreferrer noopener">forecast from&nbsp;$22&nbsp;to&nbsp;$40</a>.</li>
<li>Lineage, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LINE#NASDAQ">LINE</a>) shares escalated 11.82% after the company <a href="https://www.benzinga.com//node/43967512" target="_blank" rel="noreferrer noopener">reported fourth-quarter results</a>.</li>
<li>Erie Indemnity Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERIE#NASDAQ">ERIE</a>) stock upped 11.63% after the company reported&nbsp;<a href="https://www.benzinga.com//node/44025334" target="_blank" rel="noreferrer noopener">fourth-quarter EPS above estimates</a>.</li>
<li>Lloyds Banking Group Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYG#NYSE">LYG</a>) stock upped 11.28%.</li>
<li>Unum Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNM#NYSE">UNM</a>) stock gained 11.11% after the company announced a $3.4 billion long-term care reinsurance transaction with Fortitude Re.</li>
<li>Fair Isaac (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FICO#NYSE">FICO</a>) stock upped 11.09% after RBC Capital analyst Ashish Sabadra upgraded the stock from Sector Perform to Outperform and raised the <a href="https://www.benzinga.com/quote/fico/analyst-ratings" target="_blank" rel="noreferrer noopener">price forecast from&nbsp;$2040&nbsp;to&nbsp;$2170</a>.</li>
<li>Masimo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NASDAQ">MASI</a>)&nbsp;stock increased 11.07% after the company <a href="https://www.benzinga.com//node/43956552" target="_blank" rel="noreferrer noopener">reported better-than-expected&nbsp;results</a>. Analysts revised the <a href="https://www.benzinga.com/quote/masi/analyst-ratings" target="_blank" rel="noreferrer noopener">stock&#8217;s price forecast</a>.</li>
<li>Smith &amp; Nephew (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNN#NYSE">SNN</a>) stock rose 10.83% after the company <a href="https://www.benzinga.com/earnings" target="_blank" rel="noreferrer noopener">reported FY24 financial results</a>.</li>
<li>Anheuser-Busch InBev SA/NV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BUD#NYSE">BUD</a>) shares rose 10.79% &nbsp;after the company reported better-than-expected&nbsp;<a href="https://www.benzinga.com//node/43973849" target="_blank" rel="noreferrer noopener">fourth-quarter earnings and revenues</a>.</li>
<li>Nutanix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTNX#NASDAQ">NTNX</a>) stock rose 10.25% after the company <a href="https://www.benzinga.com//node/44007219" target="_blank" rel="noreferrer noopener">reported second-quarter results</a>. Analysts <a href="https://www.benzinga.com/quote/ntnx/analyst-ratings" target="_blank" rel="noreferrer noopener">revised the price forecast</a>.</li>
</ol>
Photo via Shutterstock

Xpeng, Li Auto And Nutanix Are Among Top 12 Large-Cap Gainers Last Week (Feb 24-Feb 28): Are The Others In Your Portfolio?

Piper Sandler analyst Jason Bednar maintains Masimo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NASDAQ">MASI</a>) with a Overweight and raises the price target from $210 to $215.

Price Target

Piper Sandler Maintains Overweight on Masimo, Raises Price Target to $215

WIIM

Masimo shares are trading higher after the company reported better-than-expected Q4 EPS and sales.

Wells Fargo analyst Vik Chopra maintains Masimo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NASDAQ">MASI</a>) with a Overweight and raises the price target from $193 to $205.

Wells Fargo Maintains Overweight on Masimo, Raises Price Target to $205

Guidance

Masimo Sees 2025 Healthcare Revenue $1.5B-$1.53B, Up 8-11% In Constant Currency

Earnings

Earnings Beats

Masimo Q4 2024 Adj. EPS $1.80 Beats $1.43 Estimate, Sales $600.700M Beat $592.444M Estimate

AHCO

ALLT

ARQT

AXGN

AXON

BASE

BGFV

BLZE

BTDR

BWIN

CART

CAVA

CBLL

CCCS

CECO

CGBD

CHRD

CIFR

CPNG

CPSS

DAWN

DNUT

DOCN

DRVN

ELAN

EXLS

FIHL

FLYW

FSLR

FULC

GPOR

HRMY

HSIC

HURN

HYLN

IART

ICCC

IGIC

IMOS

INGN

INTU

INVX

IPAR

ITRI

IVAC

JACK

JAZZ

KEYS

KNSA

LCID

LGIH

LIVN

LMND

LXFR

MATX

MFIC

MIDD

MMSI

MPLN

MRVI

NOVT

NXRT

Earnings Scheduled For February 25, 2025

In the current market session, Masimo Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NASDAQ">MASI</a>) stock price is at $179.97, after a 0.22% drop. However, over the past month, the company's stock increased by 5.38%, and in the past year, by 39.29%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is not performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1739983508_0.png" alt="Past Year Chart" />

<h3>Evaluating Masimo P/E in Comparison to Its Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Compared to the aggregate P/E ratio of 84.22 in the Health Care Equipment &amp; Supplies industry, Masimo Inc. has a higher P/E ratio of 124.39. Shareholders might be inclined to think that Masimo Inc. might perform better than its industry group. It's also possible that the stock is overvalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1739983508_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

Markets

Price Over Earnings Overview: Masimo

Masimo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NASDAQ">MASI</a>) has outperformed the market over the past 15 years by 1.57% on an annualized basis producing an average annual return of 13.6%. Currently, Masimo has a market capitalization of $9.63 billion. 
Buying $100 In MASI: If an investor had bought $100 of MASI stock 15 years ago, it would be worth $688.65 today based on a price of $179.94 for MASI at the time of writing.
<h3>Masimo's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739545208_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 15 Years Ago, You Would Have This Much Today

Masimo's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NYSE">MASI</a>) short percent of float has risen 3.23% since its last report. The company recently reported that it has 2.91 million shares sold short, which is 9.91% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.38 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Masimo Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739385921_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Masimo has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Masimo's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Masimo's peer group average for short interest as a percentage of float is 3.37%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

(MASI) - Analyzing Masimo's Short Interest

Masimo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NASDAQ">MASI</a>) has outperformed the market over the past 15 years by 1.2% on an annualized basis producing an average annual return of 13.4%. Currently, Masimo has a market capitalization of $9.41 billion. 
Buying $1000 In MASI: If an investor had bought $1000 of MASI stock 15 years ago, it would be worth $6,568.22 today based on a price of $175.70 for MASI at the time of writing.
<h3>Masimo's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738705514_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Masimo 15 Years Ago Would Be Worth Today

In the latest quarter, 7 analysts provided ratings for Masimo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NASDAQ">MASI</a>), showcasing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $186.86, a high estimate of $210.00, and a low estimate of $170.00. Marking an increase of 10.35%, the current average surpasses the previous average price target of $169.33. 
<img src="https://www.benzinga.com/files/images/story/2025/1737547255_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Masimo. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jayson Bedford</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$194.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$210.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Vik Chopra</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$193.00</td>
<td>$171.00</td>
</tr>
<tr>
<td>Rick Wise</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$190.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Jayson Bedford</td>
<td>Raymond James</td>
<td>Announces</td>
<td>Outperform</td>
<td>$170.00</td>
<td>-</td>
</tr>
<tr>
<td>Vik Chopra</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$171.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$180.00</td>
<td>$165.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Masimo. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Masimo compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Masimo's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Masimo's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/MASI/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Masimo analyst ratings.</a>
<h2>Discovering Masimo: A Closer Look</h2>
Masimo Corp is a global technology company. The company's segment includes healthcare and non-healthcare. The healthcare business segment is a key revenue driver, develops, manufactures, and markets a variety of noninvasive patient monitoring technologies, hospital automation and connectivity solutions, remote monitoring devices and consumer health products. Its non-healthcare segment includes consumer audio business develops, manufactures, markets sells and licenses premium and luxury audio sound products and related integration technologies.
<h3>Key Indicators: Masimo's Financial Health</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Over the 3 months period, Masimo showcased positive performance, achieving a revenue growth rate of 5.37% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Masimo's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 1.94%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 0.69%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Masimo's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 0.33%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Masimo's debt-to-equity ratio stands notably higher than the industry average, reaching 0.59. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into Masimo Stock: Analyst Perspectives (7 Ratings)

Katie Szyman Appointed Chief Executive Officer and to Board of Directors
Interim CEO Michelle Brennan Named Chairman of Masimo's Board
Today the Board of Directors (the "Board") of Masimo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NASDAQ">MASI</a>), a leading global medical innovator, announced that Katie Szyman has been appointed the next Chief Executive Officer ("CEO") of the Company. Interim CEO Michelle Brennan has been appointed Chairman of Masimo's Board and Lead Independent Director Quentin Koffey has been appointed Vice Chairman. All of these changes are effective as of February 12, 2025.

Management

Masimo Appoints Katie Szyman Appointed Chief Executive Officer And To Board Of Directors; Interim CEO Michelle Brennan Named Chairman Of Masimo's Board, Effective February 12, 2025.

Legal

Press Releases

SHAREHOLDER ALERT: Morris Kandinov Investigating MASI, EXTR, POWW, and EP; Shareholders are Encouraged to Contact the Firm

Masimo to Present in the 43rd Annual J.P. Morgan Healthcare Conference

The Law Offices of Frank R. Cruz Announces Investigation of Masimo Corporation (MASI) on Behalf of Investors

Masimo Announces Select Preliminary 2024 Financial Results and 2025 Guidance

Masimo Announces Leadership Transition

Masimo Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Updated Full-Year 2025 Guidance

Masimo to Present in the 46th Annual Raymond James Institutional Investor Conference

Shareholder Alert: Johnson Fistel, LLP Investigates Domino's Pizza, Masimo, Acadia Healthcare, and American Express—Long-Term Investors are Encouraged to Contact the Firm

Comments

Masimo

Unusual Options Activity for

뉴스

파트너 / 기고자

벤징가 글로벌